TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Phil Nadeau, Ph.D.

Managing Director, Health Care - Biotechnology

Headshot photo of Phil Nadeau

Philip Nadeau is a managing director and senior research analyst on the biotechnology team at TD Cowen. He joined TD Cowen in 2000 and is responsible for covering approximately 25 large-, mid-, and small-cap biotechnology stocks. TD Cowen’s biotechnology team has consistently been among the top-ranked teams in the Greenwich Survey. Dr. Nadeau has been recognized in The Wall Street Journal’s “Best on the Street” rankings and in the Institutional Investor poll. His views on biotechnology topics are often quoted by national news services such as Reuters, Bloomberg and the Dow Jones newswires. Prior to joining TD Cowen, he was a research assistant at Children’s Hospital, Boston.

Dr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a Ph.D. in Neurobiology from Harvard University. 

Get In Touch

Start a conversation with Phil Nadeau


    Explore related thought leadership, reports, coverage and insights for Phil Nadeau.

    Pill bottle is placed in the hands of an elderly recipient.
    Ahead of the Curve®

    Pipeline Success Rates Correlate With Biotech Valuations

    A chemist in a lab is taking precaution as he conducts research in full protective gear towards the end of biodefense.
    Ahead of the Curve®

    A New Chapter In Biosecurity: Are We Prepared?

    A son, older in age and dressed in a red and blue collored shirt holds the hand of his ailing elderly mother with both of his own hands.
    Ahead of the Curve®

    Alzheimer’s Coming of Age Moment